|
The following information can be downloaded and given to your patients to help them better understand and manage alpha1-antitrypsin (AAT) deficiency. Be sure to check back frequently, as new tools will be added on an ongoing basis.
You need the Adobe® Reader® installed on your computer to view PDFs. You can download
a copy of the Adobe Reader by clicking the link below.
|
|
| Adobe and Adobe Reader are registered trademarks of Adobe Systems Incorporated. |
Important facts about AAT deficiency.
What is Alpha1–Antitrypsin Deficiency? (PDF)
What does it mean to be an Alpha1 Carrier? (PDF)
Guide to the Recently Diagnosed (PDF)
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|